TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03988673

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid with implicit values clarification method (booklet or website)
Description: The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid with explicit values clarification method (booklet or website)
Description: The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
Study: NCT02379507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEC033 Study Product
Description: Apply twice daily
Study: NCT04647994

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 serology
Description: Serology test of SARS-CoV-2 for pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 serology
Description: Serology test of SARS-CoV-2 for pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 serology
Description: Serology test of SARS-CoV-2 for pregnant women

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 serology
Description: Serology test of SARS-CoV-2 for pregnant women
Study: NCT03252366

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GELFOAM
Description: * Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft
Description: * Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study: NCT02357615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine CR tablets (Xin Ran)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalat
Study: NCT02163642

Intervention type: DEVICE
Intervention: Cyranose® 320
Description: Detection of patterns of specific Volatile Organic Compounds in exhaled air
Study: NCT03296566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Liaison
Description: An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
Study: NCT00526097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg
Description: 2 x 5 mg bisacodyl once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
Study: NCT04591262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06826647-LR 600 mg PO
Description: 14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 600 mg PO
Description: Unlabeled PF-06826647 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06826647 100 ug IV
Description: 14C-PF-06826647 100 ug IV
Study: NCT02627768

Intervention type: DRUG
Intervention: No Intervention
Description: Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.

Intervention type: DRUG
Intervention: No Intervention
Description: Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
Study: NCT03305887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRATAFIX™ Symmetric Knotless Tissue
Description: This devices will be used in deep and intermediate layers of barbed suture group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VICRYL® PLUS
Description: This devices will be used in deep and intermediate layers of conventional suture group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRATAFIX Spiral sutures
Description: This devices will be used in intradermal layer of both barbed suture and conventional suture group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATAFIX Spiral sutures
Description: This devices will be used in intradermal layer of both barbed suture and conventional suture group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMABOND™ Advance™ Skin Closure System
Description: This devices will be used in skin layer of both barbed suture and conventional suture group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND™ Advance™ Skin Closure System
Description: This devices will be used in skin layer of both barbed suture and conventional suture group.
Study: NCT02396446

Intervention type: OTHER
Intervention: Abdominal acoustic measurement
Description: Device meant to listen to the sounds of the gut to determine post op ileus.
Study: NCT02718547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combigan
Description: Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
Study: NCT00630552

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dummy of AMG 655.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
Study: NCT00721214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
Study: NCT03433183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
Study: NCT02230293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assistance
Description: Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow up
Description: Assistance was effected by physician and nurse and consisted about adapting to the drug
Study: NCT00038155

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ambulation training
Description: Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
Study: NCT03745378

Intervention type: OTHER
Intervention: JAK2V617F mutation
Description: JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,

Intervention type: OTHER
Intervention: JAK2V617F mutation
Description: JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
Study: NCT03866980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: PO
Study: NCT01284309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02719262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: installing ventilation in the workplace
Description: Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
Study: NCT01178307

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 10 minutes to complete 3 questionnaires for development of MDASI-GIST

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 10 minutes to complete 3 questionnaires for development of MDASI-GIST

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Each interview will take approximately 30 minutes.

Intervention type: BEHAVIORAL
Intervention: MDASI-GIST Questionnaire
Description: Every 4 weeks for one year
Study: NCT03459859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
Study: NCT01808898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anaesthetic
Description: On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local Anaesthetic
Description: On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
Study: NCT02168231

Intervention type: PROCEDURE
Intervention: Complex abdominal wall repair Strattice
Description: Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
Study: NCT02363998

Intervention type: DRUG
Group type: OTHER
Intervention: Lofexidine
Description: All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
Study: NCT02267564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MPFL reconstruction
Description: to correct patellar dislocation with medial patellofemoral ligament reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction
Description: to correct patellar dislocation with medial patellofemoral ligament reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tibial tubercle transfer
Description: to correct patellar dislocation with tibial tubercle medial transfer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tibial tubercle transfer
Description: to correct patellar dislocation with tibial tubercle medial transfer
Study: NCT03788122

Intervention type: OTHER
Group type: OTHER
Intervention: In-depth interview
Description: The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
Study: NCT04959578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
Study: NCT03616860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound (FUS) BBB Disruption
Description: FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
Study: NCT02162017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The lying flat (0°) head position for 24 hours
Description: The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The sitting-up (≥30°) head position for 24 hours
Description: For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
Study: NCT05444036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
Study: NCT00175045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
Study: NCT04308213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marrow Cellution System
Description: The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
Study: NCT01858051

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01395498

Intervention type: OTHER
Intervention: laboratory testing of PCP and CMV genetic material
Description: laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
Study: NCT00392535

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy 74 Gy delivered in 37 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy 60 Gy in 20 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy 57 Gy in 19 fractions
Study: NCT03962764

Intervention type: BEHAVIORAL
Intervention: Responsible Fatherhood Program
Description: 24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
Study: NCT01903083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive 3 doses of radiation (8-10 Gy per fraction).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Description: Surgical resection.
Study: NCT02732002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCBRA ( Objective Criteria Based REhabilitation Algorithm
Description: The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
Study: NCT03669328

Intervention type: PROCEDURE
Intervention: locoregional anesthesia
Description: Both groups received locoregional anesthesias

Intervention type: PROCEDURE
Intervention: locoregional anesthesia
Description: Both groups received locoregional anesthesias
Study: NCT02476747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Description: performing EMR for patients with small polyp

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSP
Description: performing CSP for patients with small polyp
Study: NCT00694798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w
Description: Immunomodulator